The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …

In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of
disease progression or death by 63% and increased the overall response rate (ORR) versus …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …

Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple
myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide …

Purpose In the ASPIRE study of carfilzomib, lenalidomide, and dexamethasone (KRd)
versus lenalidomide plus dexamethasone (Rd) in patients with relapsed or refractory …

Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow plasma cells or …